DRY-CID label update clarifies machine-specific hemodialysis preparation
The latest DailyMed label for DRY-CID, a dry concentrate for hemodialysis powder for solution, spells out a product built for a narrow and highly technical clinical task: preparing dialysate for use with 3-pump hemodialysis machines only. The label also identifies the product as an unapproved drug other, a designation that places extra weight on correct compounding, dilution, and equipment compatibility because the final fluid delivered to patients must be chemically exact even when the starting material is a dry concentrate.
A single mismatch in dilution or machine setup can change the electrolyte profile of the bath.
The formulation is built around potassium chlorate as the active ingredient, with sodium chloride, calcium chloride anhydrous, magnesium chloride anhydrous, acetic acid, and anhydrous dextrose listed among the inactive ingredients. Once diluted to 20 gallons, or 75.70 liters, one part acid concentrate with 44 parts purified water, the label specifies target concentrations of sodium 100.00 mEq/L, potassium 2.00 mEq/L, calcium 2.50 mEq/L, magnesium 1.00 mEq/L, chlorides 105.50 mEq/L, acetate 4.00 mEq/L, and dextrose 100.00 mg/dL. The calculated final conductivity at 25°C is listed as 13.2 to 14.2 mS/cm, a range that matters because conductivity is one of the most immediate checks that the concentrate has been prepared into a dialysate with the intended ionic strength.
In hemodialysis, the bath is not passive background fluid. It is the medium through which solute removal, acid-base correction, and electrolyte balance are negotiated session by session. Sodium concentration influences plasma tonicity and intradialytic stability; potassium concentration directly shapes the gradient for potassium removal; calcium and magnesium affect neuromuscular and cardiovascular physiology; acetate serves as a buffer precursor; and dextrose can modify osmotic behavior. Even small deviations in any of these components can alter patient tolerance, especially in people whose cardiac rhythm, blood pressure, or electrolyte reserves are already precarious.
Dilution instructions define the safety boundary around the concentrate
The label does not leave dilution to interpretation. It repeatedly instructs users to dilute one part of the acid concentrate with 44 parts of purified water, using purified water that meets ISO 13959:2014 or, in one section, purified water under Standard 13959:2014. It also specifies use in combination with sodium bicarbonate. That pairing reflects standard dialysis chemistry: the acid concentrate provides a controlled acid load and essential ions, while the bicarbonate component completes the dialysate formulation needed to support metabolic correction during treatment.
This kind of product lives or dies by adherence to procedure. The concentrate is intended for use only with 3-pump hemodialysis machines, and the label warns against using it if the warranty seal is damaged or broken, or if debris could fall into the concentrate. Those instructions may sound procedural, but they are clinical safeguards. Any contamination or misloading of the concentrate can translate into the delivery of an unsafe dialysate, with consequences ranging from ineffective clearance to acute electrolyte disturbance.
The storage and handling directions are straightforward: store at room temperature and keep the container tightly closed when not in use. If the entire contents are not used, the excess should be discarded. For a product that depends on exact dilution and controlled final chemistry, partial reuse would introduce unnecessary uncertainty into a process that should remain standardized from box to machine to patient.
The packaging details place the product in a 25.28 kg box under NDC 81943-601-01, with Aqua Medica, S.A. de C.V. listed as the labeler and manufacturer. The marketing history shows a start date of March 30, 2023 for the marketing category and August 30, 2023 for the package. DailyMed lists the label update date as October 16, 2026, and the version history identifies this as version 4.
For dialysis units, the practical meaning of this label is not subtle. Hemodialysis depends on a precisely engineered fluid environment, and the concentrate must integrate with the machine architecture, water quality, and bicarbonate system without deviation. A dry concentrate may look simple on paper, but in practice it determines whether the session delivers the intended electrolyte composition and conductivity. In a therapy where patients can be exposed to large volume shifts over a few hours, chemistry is bedside care.
The label also carries the usual patient-safety language: keep out of reach of children, and if swallowed, get medical help or contact a Poison Control Center right away. While that warning is not dialysis-specific, it reinforces the fact that this is a chemical preparation requiring controlled handling rather than a routine consumer product. The active and inactive ingredients, the dilution ratio, the water standard, and the machine restriction together define the boundaries of acceptable use.
No efficacy trial is attached to this label update, and no comparative clinical outcome data appear in the material. The important issue here is formulation control. For a hemodialysis concentrate, the central clinical question is whether the final dialysate is produced exactly as intended, because the patient never receives the concentrate itself; the patient receives the consequences of its dilution, buffering, and ionic composition. Any further assessment would depend on real-world compatibility data, machine-specific validation, and safety surveillance in actual dialysis operations.